Cao Xiao-Zheng, Zhang Yao-Feng, Song Yu-Wei, Yuan Lei, Tang Hui-Li, Li Jin-Yuan, Qiu Ye-Bei, Lin Jia-Zhi, Ning Ying-Xia, Wang Xiao-Yu, Xu Yong, Lin Shao-Qiang
Guangdong Provincial Engineering Research Center for Esophageal Cancer Precise Therapy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510062, Guangdong Province, China.
Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, Guangdong Province, China.
World J Stem Cells. 2025 Mar 26;17(3):99472. doi: 10.4252/wjsc.v17.i3.99472.
Cervical cancer (CC) stem cell-like cells (CCSLCs), defined by the capacity of differentiation and self-renewal and proliferation, play a significant role in the progression of CC. However, the molecular mechanisms regulating their self-renewal are poorly understood. Therefore, elucidation of the epigenetic mechanisms that drive cancer stem cell self-renewal will enhance our ability to improve the effectiveness of targeted therapies for cancer stem cells.
To explore how DNA methyltransferase 1 (DNMT1)/miR-342-3p/Forkhead box M1 (FoxM1), which have been shown to have abnormal expression in CCSLCs, and their signaling pathways could stimulate self-renewal-related stemness in CCSLCs.
Sphere-forming cells derived from CC cell lines HeLa, SiHa and CaSki served as CCSLCs. Self-renewal-related stemness was identified by determining sphere and colony formation efficiency, CD133 and CD49f protein level, and SRY-box transcription factor 2 and octamer-binding transcription factor 4 mRNA level. The microRNA expression profiles between HeLa cells and HeLa-derived CCSLCs or mRNA expression profiles that HeLa-derived CCSLCs were transfected with or without miR-342-3p mimic were compared using quantitative PCR analysis. The expression levels of mRNA, miR-342-3p, and FoxM1 protein were examined by quantitative real-time PCR and western blotting. carcinogenicity was assessed using a mouse xenograft model. The functional effects of the DNMT1/miR-342-3p/FoxM1 axis were examined by and gain-of-activity and loss-of-activity assessments. Interplay among DNMT1, miR-342-3p, and FoxM1 was tested by methylation-specific PCR and a respective luciferase reporter assay.
CCSLCs derived from the established HeLa cell lines displayed higher self-renewal-related stemness, including enhanced sphere and colony formation efficiency, increased CD133 and CD49f protein level, and heightened transcriptional quantity of stemness-related factors SRY-box transcription factor 2 and octamer-binding transcription factor 4 as well as a stronger tumorigenic potential compared to their parental cells. Moreover, quantitative PCR showed that the level was downregulated in HeLa-derived CCSLCs compared to HeLa cells. Its mimic significantly decreased and mRNA expression levels in CCSLCs. Knockdown of or mimic transfection suppressed expression, increased quantity by promoter demethylation, and inhibited CCSLC self-renewal. Inhibition of FoxM1 by shRNA transfection also resulted in the attenuation of CCSLC self-renewal but had little effect on the DNMT1 activity and miR-342-3p expression. Furthermore, the loss of CCSLC self-renewal exerted by miR-342-3p mimic was inverted by the overexpression of DNMT1 or FoxM1. Furthermore, DNMT1 and FoxM1 were recognized as straight targets by miR-342-3p in HeLa-derived CCSLCs.
Our findings suggested that a novel DNMT1/miR-342-3p/FoxM1 signal axis promotes CCSLC self-renewal and presented a potential target for the treatment of CC through suppression of CCSLC self-renewal. However, this pathway has been previously implicated in CC, as evidenced by prior studies showing miR-342-3p-mediated downregulation of FoxM1 in cervical cancer cells. Additionally, research on liver cancer further supports the involvement of miR-342-3p in suppressing FoxM1 expression. While our study contributed to this body of knowledge, we did not present a completely novel axis but reinforced the therapeutic potential of targeting the DNMT1/miR-342-3p/FoxM1 axis to suppress CCSLC self-renewal in CC treatment.
宫颈癌(CC)干细胞样细胞(CCSLCs)具有分化、自我更新和增殖能力,在CC进展中起重要作用。然而,调节其自我更新的分子机制尚不清楚。因此,阐明驱动癌症干细胞自我更新的表观遗传机制将提高我们改善癌症干细胞靶向治疗有效性的能力。
探讨在CCSLCs中已显示表达异常的DNA甲基转移酶1(DNMT1)/微小RNA-342-3p(miR-342-3p)/叉头框M1(FoxM1)及其信号通路如何刺激CCSLCs中与自我更新相关的干性。
从CC细胞系HeLa、SiHa和CaSki衍生的成球细胞用作CCSLCs。通过测定成球和集落形成效率、CD133和CD49f蛋白水平以及SRY盒转录因子2和八聚体结合转录因子4 mRNA水平来鉴定与自我更新相关的干性。使用定量PCR分析比较HeLa细胞与HeLa衍生的CCSLCs之间的微小RNA表达谱,或HeLa衍生的CCSLCs转染有或无miR-342-3p模拟物后的mRNA表达谱。通过定量实时PCR和蛋白质印迹检测mRNA、miR-342-3p和FoxM1蛋白的表达水平。使用小鼠异种移植模型评估致癌性。通过增益和失活评估来检测DNMT1/miR-342-3p/FoxM1轴的功能作用。通过甲基化特异性PCR和相应的荧光素酶报告基因检测来测试DNMT1、miR-342-3p和FoxM1之间的相互作用。
源自已建立的HeLa细胞系的CCSLCs表现出更高的与自我更新相关的干性,包括增强的成球和集落形成效率、增加的CD133和CD49f蛋白水平、干性相关因子SRY盒转录因子2和八聚体结合转录因子4转录量的增加以及与亲代细胞相比更强的致瘤潜力。此外,定量PCR显示,与HeLa细胞相比,HeLa衍生的CCSLCs中miR-342-3p水平下调。其模拟物显著降低了CCSLCs中SRY盒转录因子2和八聚体结合转录因子4的mRNA表达水平。敲低DNMT1或miR-342-3p模拟物转染抑制了FoxM1表达,通过启动子去甲基化增加了SRY盒转录因子2和八聚体结合转录因子4的量,并抑制了CCSLCs的自我更新。通过shRNA转染抑制FoxM1也导致CCSLCs自我更新的减弱,但对DNMT1活性和miR-342-3p表达影响很小。此外,miR-342-3p模拟物导致的CCSLCs自我更新丧失被DNMT1或FoxM1的过表达所逆转。此外,在HeLa衍生的CCSLCs中,DNMT1和FoxM1被miR-342-3p识别为直接靶点。
我们的研究结果表明,一种新的DNMT1/miR-342-3p/FoxM1信号轴促进CCSLCs的自我更新,并通过抑制CCSLCs的自我更新为CC治疗提供了一个潜在靶点。然而,该途径先前已涉及CC,先前的研究表明miR-342-3p介导宫颈癌细胞中FoxM1的下调证明了这一点。此外,对肝癌的研究进一步支持miR-342-3p参与抑制FoxM1表达。虽然我们的研究为这一知识体系做出了贡献,但我们并未提出一个全新的轴,而是加强了靶向DNMT1/miR-342-3p/FoxM1轴以抑制CC治疗中CCSLCs自我更新的治疗潜力。